二甲双胍对单纯性肥胖患者血清MCP-1水平及体成分的影响

目的：探讨二甲双胍对单纯性肥胖患者空腹血清单核细胞趋化蛋白 1（monocyte chemoattractant protein 1, MCP 1）水平与体成分的影响及与体成分的相关性。方法：采用酶联免疫法和生物电阻抗仪分别测定单纯性肥胖患者、健康对照者以及经二甲双胍治疗12周后的肥胖患者的空腹血清MCP 1水平和体成分，对MCP 1水平和体成分进行分组比较，并分析与体成分相关性。结果：单纯性肥胖患者血清MCP 1水平明显高于健康对照者（P＜0.05）；肥胖患者经二甲双胍治疗后血清MCP 1水平显著降低（P＜0.05）；相关分析显示：血清MCP 1水平与体重指数（body mass index，BMI）（r=0.326, P＜0.05）、腰围（r=0.344, P＜0.05）呈正相关。结论：单纯性肥胖患者MCP 1水平较正常人高，二甲双胍治疗可以降低血清MCP 1水平，从而改善致动脉粥样硬化的炎性反应。

Effect of metformin on serum mcp-1 and body composition in simple obese patients

Objective: To investigate the effect of metformin on serum level of monocyte chemoattractant protein-1(MCP-1) and body compositon in obese patients and the correlation between MCP-1 and body composition.Methods: Fasting serum level of MCP-1 was assayed by ELISA in controls,obese patients,and patients accepted 12-week treatment with metformin.Body composition was detected by bioelectrical impedance analysis in all objects.The differences of MCP-1 and body composition among different groups and the relations between serum level of MCP-1 and body composition were also analyzed.Results: Serum level of MCP-1 in obese patients was significantly increased compared with controls(P<0.05),while serum level of MCP-1 in patients treated with metformin for 12 weeks was significantly decreased(P<0.05).Serum MCP-1 levels positively correlated with body mass index(BMI)(r= 0.326,P<0.05) and waist circumference(r=0.344,P<0.05).Conclusion: Obese patients exhibit a increased serum level of MCP-1.Metformin can decrease the circulating MCP-1 level and improve the inflammatory processes involved in atherogenesis.